about
Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes.A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myelomaImmunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myelomaSuperiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma.Role of plasmacytoid dendritic cells in immunity and tolerance after allogeneic hematopoietic stem cell transplantation.Current state of art for transplantation paradigms in peripheral T-cell lymphomas.Autologous stem cell transplantation for T-cell lymphomas.AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition.HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment.Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma.Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency.Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma.Acute graft-versus-host disease and steroid treatment impair CD11c+ and CD123+ dendritic cell reconstitution after allogeneic peripheral blood stem cell transplantation.Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma.First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma.The value of 18F-FDG PET/CT after autologous stem cell transplantation (ASCT) in patients affected by multiple myeloma (MM): experience with 77 patients.Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation.A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma.Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myelomaLong-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myelomaEvaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocationLong-term follow-up after autologous stem cell transplantation for light- and heavy-chain deposition diseaseComplete remission upon bortezomib–dexamethasone therapy in three heavily pretreated multiple myeloma patients relapsing after allogeneic stem cell transplantationOsteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasoneAutoimmune diseases during treatment with immunomodulatory drugs in multiple myeloma: selective occurrence after lenalidomide
P50
Q33409172-F5D42571-FECE-4997-BBD9-258B62186D67Q33944281-09955FCF-59FF-4CF8-9A39-84B003F31B76Q34369823-19F2CDFF-D04D-42F6-BE63-5F3F366DC790Q34401962-FA85AE9D-C5F8-46A9-AAC7-829A934D2AFAQ35216482-69E0F811-6B36-4598-BE2C-63363EB711F4Q38132821-5EFF570F-6A71-4618-964B-F73B797CACB5Q38182255-D66C3D6E-06D6-4553-89ED-B273BDD07A39Q38597474-2106FC19-83B3-4FA5-BB23-9799DBAF80C0Q38953187-19B6814A-FB2C-41F1-B99F-D0E0CEFD5A05Q39718152-DD68B9B7-3A6F-4BF6-9819-4BDE0522E304Q43144824-CE4F1A8B-D628-422A-B1EF-21FFB27C98F3Q43282882-3551F919-B496-4610-BC45-E3407C4F9092Q45119325-5220E174-9DD8-43FB-A860-009E262F296DQ45252391-3A59F225-D544-44BC-8961-1543F5C23391Q46946161-21C15908-AD37-4B68-BA28-B6B445160AFAQ53134754-FC43CB60-A3C8-45A2-B2BB-33FA02A30861Q53203772-D125657E-0BD8-4B1F-A84A-D93DFFBD69E0Q53503721-251D9273-9F33-4910-8229-C901EA1530DBQ56981141-39027A5B-65BC-4065-888B-4A80FF6F9AB1Q56982314-34DDE19C-E678-4232-95FF-DD9B27982DFFQ56993837-F082648F-3CC0-4707-86C4-B6840439B18CQ57904003-DCA0894D-67FB-490A-8CF5-20A257B2516DQ57904051-2EACED66-18D4-4EF2-93C9-BB867C0D0AE1Q57904055-E21EE72B-7DD9-4835-9EA4-797AFB1A7C4AQ61043528-C65E5637-65E3-4238-889F-42BEE1C06E09
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Giulia Perrone
@ast
Giulia Perrone
@en
Giulia Perrone
@es
Giulia Perrone
@nl
Giulia Perrone
@sl
type
label
Giulia Perrone
@ast
Giulia Perrone
@en
Giulia Perrone
@es
Giulia Perrone
@nl
Giulia Perrone
@sl
prefLabel
Giulia Perrone
@ast
Giulia Perrone
@en
Giulia Perrone
@es
Giulia Perrone
@nl
Giulia Perrone
@sl
P1053
L-4565-2017
P106
P1153
7006216652
P21
P31
P3829
P496
0000-0002-4312-0577